Art

J-GLOBAL ID：201702223599096661   Reference number：17A0958644

Effect of vitamin K₂ on the anticoagulant activity of warfarin during the perioperative period of catheter ablation: Population analysis of retrospective clinical data

カテーテルアブレーション周術期中のワーファリン抗凝固活性に及ぼすビタミンK₂の効果

Author (12)： ZHOU Zhi (Kyoto Univ. Hospital, Sakyo-ku, JPN) ,  ZHOU Zhi (Kyoto Univ., Sakyo-ku, JPN) ,  YANO Ikuko (Kyoto Univ. Hospital, Sakyo-ku, JPN) ,  YANO Ikuko (Kyoto Univ., Kyoto, JPN) ,  ODAKA Sumiko (Kyoto Univ. Hospital, Sakyo-ku, JPN) ,  MORITA Yosuke (Kyoto Univ. Hospital, Sakyo-ku, JPN) ,  SHIZUTA Satoshi (Kyoto Univ., Sakyo-ku, JPN) ,  HAYANO Mamoru (Kyoto Univ., Sakyo-ku, JPN) ,  KIMURA Takeshi (Kyoto Univ., Sakyo-ku, JPN) ,  AKAIKE Akinori (Kyoto Univ., Sakyo-ku, JPN) ,  INUI Ken-ichi (Kyoto Univ. Hospital, Sakyo-ku, JPN) ,  MATSUBARA Kazuo (Kyoto Univ. Hospital, Sakyo-ku, JPN)
Material： Journal of Pharmaceutical Health Care and Sciences (Web)
Volume： 2  Page： 2:17 (WEB ONLY)  Publication year： 2016 
JST Material Number： U1100A  ISSN： 2055-0294  Document type： Article
Article type： 原著論文  Country of issue： United Kingdom (GBR)  Language： ENGLISH (EN)

Thesaurus term： *Catheter Ablation ,...
Semi thesaurus term： *vitamin K2 ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=17A0958644&from=J-GLOBAL&jstjournalNo=U1100A") }}

JST classification (3)： Clinical biopharmacy  (GY01022L) ,  Fibrinolysis and blood coagulation  (EJ03040S) ,  Treatment for cardiovasular system diseases in general  (GJ05010B)

Substance index (1)： Warfarin potassium

Reference (25)：

• Haïssaguerre M, Jaïs P, Shah D, Takahashi A, Hocini M, Quiniou G, Garrigue S, Le Mouroux A, Le Métayer P, Clémenty J. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med. 1998;339:659-66.
• Wellens H. Atrial fibrillation-the last big hurdle in treating supraventricular tachycardia. N Engl J Med. 1994;331:944-5.
• trial Fibrillation Investigators: Atrial Fibrillation, Aspirin, Anticoagulation Study; Boston Area Anticoagulation Trial for Atrial Fibrillation Study; Canadian Atrial Fibrillation Anticoagulation Study; Stroke Prevention in Atrial Fibrillation Study; Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Study. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: Analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994;154:1449-57.
• Higashi M, Veenstra D, Kondo L, Wittkowsky A, Srinouanprachanh S, Farin F, Rettie A. Association between CYP2C9 genetic variants and anticoagulationrelated outcomes during warfarin therapy. J Am Med Assoc. 2002;287:1690-8.
• Obayashi K, Nakamura K, Kawana J, Ogata H, Hanada K, Kurabayashi M, Hasegawa A, Yamamoto K, Horiuchi R. VKORC1 gene variations are the major contributors of variation in warfarin dose in Japanese patients. Clin Pharmacol Ther. 2006;80:169-78.

Terms in the title (5)： カテーテルアブレーション ,  周術期 ,  ワーファリン ,  抗凝固活性 ,  ビタミンK2